RandyW Posted September 7, 2008 Share Posted September 7, 2008 Celgene's Lung Cancer Drug Gets FDA 'Fast Track' Approval By Shankar P. 9/4/2008 Celgene Corp. (Nasdaq: CELG), a pharmaceutical company based in Summit, today announced that its lung cancer drug, "Amrubicin," has been granted "fast track" approval by the U.S. Food and Drug Administration. Amrubicin is for the treatment of small cell lung cancer after chemotherapy, the company said in a statement. The FDA grants "fast track" designation for a drug that treats "a serious or life-threatening condition," Celgene said. Drugs with fast-track designations could potentially get expedited regulatory approvals, according to the company. Small cell lung cancer is a disease in which malignant cells form in the tissues of the lung; it occurs almost exclusively in people who smoke, Celgene said. Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.